Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Conditions: Chronic Kidney Disease Interventions: Drug: Part A - Lorundrostat QD + Dapaglifozin QD; Drug: Part A - Lorundrostat QD; Drug: Part B - Lorundrostat QD Open Label Sponsors: Mineralys Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
Conditions: Compensated Cirrhosis; Decompensated Cirrhosis Interventions: Drug: Metformin; Drug: Sitagliptin; Drug: Dapagliflozin Sponsors: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
Conditions: Kidney Transplant; Complications; Vascular Diseases; Diabetes Interventions: Drug: Dapagliflozin 10mg Tab; Drug: Placebo Sponsors: University of Colorado, Denver Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 20, 2023 Category: Research Source Type: clinical trials
Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets
Conditions: Healthy Interventions: Drug: Dapagliflozin 10 mg film-coated tablet; Drug: Forxiga ® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia Sponsors: Dexa Medica Group; PT Equilab International Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes
Conditions: Insulin Pump ，Continuous Glucose Monitoring Technology Interventions: Drug: Insulin Glargine; Drug: Metformin; Drug: Dapagliflozin; Drug: Insulin aspart Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Zibotentan/Dapagliflozin Combination Demonstrated Significant Albuminuria Reduction in Patients with Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial
52.5% reduction with high-dose and 47.7% reduction with low-dose combination compared to baseline, and an acceptable tolerability profile
Novel investigational drug leverages SGLT2 inhibition and high selectivity ETA receptor antagonism with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
Conditions: Lupus Nephritis Interventions: Drug: Dapagliflozin 10mg Tab orally once daily Sponsors: Ain Shams University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
Conditions: Cardiorenal Syndrome Interventions: Drug: Dapagliflozin Sponsors: Yale University; American Heart Association Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation
Conditions: Atrial Fibrillation Recurrent; Catheter Ablation Interventions: Drug: Dapagliflozin 10 mg [Farxiga] Sponsors: Chang Gung Memorial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance
Conditions: Heart Failure Interventions: Diagnostic Test: myocardial function after surgery Sponsors: Ain Shams University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Conditions: Chronic Kidney Disease With High Proteinuria Interventions: Drug: Zibotentan/Dapagliflozin; Drug: Dapagliflozin Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
Conditions: Heart Failure; Reduced Ejection Fraction Heart Failure Interventions: Drug: Empagliflozin 10 MG; Drug: Dapagliflozin 10 MG Sponsors: Damanhour University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.
Conditions: Hypertension; Diabetes Mellitus, Type 2 Interventions: Drug: THP-00101 (Dapagliflozin) 10mg; Drug: THP-00102 (Telmisartan) 80mg Sponsors: THPharm Corp. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga ®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome
Conditions: Nephrotic Syndrome; Sodium-Glucose Transporter 2 Inhibitors Intervention: Drug: Dapagliflozin 10mg Tab Sponsor: Ain Shams University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
